A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma.

Joseph I ClarkJatinder SinghMarc S ErnstoffChristopher D LaoLawrence E FlahertyTheodore F LoganBrendan CurtiSanjiv S AgarwalaBret TabackLee CranmerJose LutzkyTheresa L LunaSandra AungDavid H Lawson

Published in: Journal for immunotherapy of cancer (2018)

NCTN, NCT01683188. Registered 11 September 2012, http://www.clinicaltrials.gov/NCT01683188.

Keyphrases

phase ii study
high dose
open label
locally advanced
low dose
stem cell transplantation
placebo controlled
metastatic colorectal cancer
rectal cancer
wild type
squamous cell carcinoma
radiation therapy
randomized controlled trial